Last month, The Journal of Family Practice offered a review of the most effective nondrug options for I.B.S. The reason for this is that I.B.S. drug treatments often don’t work for many patients or pose serious health risks. The drug Zelnorm was withdrawn after links to heart problems, and the drug Lotronex has been subjected to severe marketing restrictions because of concerns about side effects.
Here is the link to the article from the NY Times: